Vitro Biopharma, Inc

About Us

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, MSC-Gro™ optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix®, Inc. to jointly manufacture and distribute LUMENESC™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Vitro Biopharma Launches New Website

Wed, May 09, 2012 15:30 CET

Golden, Colorado—May 9, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the launch of a completely revised new website at www.vitrobiopharma.com. Vitro Biopharma is focused on providing unique tools for stem cell research and clinical development based on adult stem cells known as Mesenchymal Stem Cells or MSCs. These adult stem cells represent the fastest growing segment of the stem cell industry largely because of the availability of these cells from several tissue sources and the ever-increasing evidence for clinical effectiveness in the treatment of a

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Vitro Biopharma Launches New Website

Media